Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Enviomycin. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enviomycin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Enviomycin. |
| Dicoumarol | The risk or severity of bleeding can be increased when Enviomycin is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Enviomycin is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Enviomycin is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Enviomycin is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Enviomycin is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Enviomycin is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Enviomycin is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Enviomycin is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Enviomycin is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Enviomycin is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Enviomycin is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Enviomycin is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Enviomycin is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Enviomycin is combined with (S)-Warfarin. |
| Lactulose | The therapeutic efficacy of Lactulose can be decreased when used in combination with Enviomycin. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Enviomycin. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Enviomycin. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Enviomycin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Enviomycin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Quinisocaine. |
| Cisatracurium | Enviomycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Enviomycin is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enviomycin. |